公开(公告)号：US20240279234A1

公开(公告)日：2024-08-22

申请号：US18644865

申请日：2024-04-24

申请人： Duke University ,  UTI Limited Partnership

发明人： Timothy A.J. Haystead ,  David A. Carlson ,  Douglas H. Weitzel ,  Justin A. MacDonald ,  Michael P. Walsh

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377

CPC分类号： C07D487/04 ,  A61K31/519 ,  A61K31/5377

摘要： The present disclosure is directed to compounds that may selectively inhibit Death Associated Protein Kinases (DAPKs) as well as PIM kinases. The compounds can be used in methods of treating various disorders, including cancers.

公开(公告)号：US20240116893A1

公开(公告)日：2024-04-11

申请号：US18273843

申请日：2022-01-25

申请人： Duke University

发明人： Scott Scarneo ,  Philip F. Hughes ,  Andrea Neely ,  Timothy A.J. Haystead

IPC分类号： C07D401/06 ,  A61P11/00 ,  A61P19/02 ,  A61P25/02

CPC分类号： C07D401/06 ,  A61P11/00 ,  A61P19/02 ,  A61P25/02

摘要： The present disclosure provides compounds according to Formula (I),






wherein X, R2, R3, R4, and R5 are defined herein. Further disclosed herein are pharmaceutical compositions, orally administrable dosage forms, and methods for using such compounds in the treatment of various diseases and disorders including inflammation, autoimmune disorders, chronic pain and cancer. In particular embodiments, the present disclosure provides orally bioavailable compounds capable of selectively modulating an activity (e.g., inhibition) of the serine/threonine protein kinase TAK1 and/or related kinases.